Detailed Narrative
US Market Resilience and New Launches
The US market remains Gland's primary growth engine, with revenue rising 8% YoY to ₹8,005 million in Q2. Growth was driven by a 10% increase in volume and a 7% contribution from new launches, offsetting flat pricing. Key launches during the quarter included Daptomycin-RTU and Sumatriptan. Management highlighted that their top 20 molecules have a market share of 25% or higher, with some reaching 40%, demonstrating strong competitive positioning despite a challenging generic environment.
Cenexi Turnaround Nears Inflection Point
Cenexi's integration is progressing with a focus on cost optimization and product mix improvement. Revenue grew 8% in Euro terms to €40 million, while EBITDA losses were halved to €5 million compared to the previous year. Management is targeting a revenue run rate of €50 million starting Q3 FY26, which is expected to bring the subsidiary to EBITDA breakeven. Infrastructure upgrades at the Fontenay site are complete, and GMP certification has been renewed through 2026.
Strategic Pivot to GLP-1 and Biologics
Gland is aggressively expanding its high-end CDMO capabilities, particularly in the GLP-1 and biologics space. Cartridge fill-finish capacity is being scaled from 40 million to 140 million units by mid-2026 to support insulin and GLP-1 programs. The company has already launched Liraglutide with a partner and has three Semaglutide contracts in the pipeline. In biologics, capacity is being expanded from 8 KL to 23 KL to capture emerging biosimilar opportunities, with revenue from Dr. Reddy's (DRL) collaboration already starting to flow.
H2 FY26 Outlook and Revenue Guidance
Despite a relatively modest 7% growth in H1, management reiterated its mid-teen consolidated revenue growth guidance for the full year. This implies a significant acceleration in H2, which management expects to be 'even stronger' due to the launch of Dalbavancin and the commencement of the Enoxaparin supply to Civica. The base business continues to operate at high efficiency, maintaining adjusted EBITDA margins at 37%, well above the long-term target of 35%.
R&D Intensity and Complex Portfolio Focus
R&D spend spiked to 5.8% of revenue this quarter as the company focuses on complex injectables and next-generation delivery systems. Gland filed 6 ANDAs and received 5 approvals during the quarter. The pipeline includes 20 RTU bag products (14 approved) and 15 products under active development in high-potential categories, including seven 505(b)(2) filings. This shift toward complex, high-entry-barrier products is central to Gland's strategy to improve Return on Capital Employed (ROCE) and margin resilience.